Estonie - estonien - Ravimiamet

alembic pharmaceuticals europe limited - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+5mg+12,5mg 98tk; 40mg+5mg+12,5mg 30tk; 40mg+5mg+12,5mg 28tk; 40mg+5mg+12,5mg 90tk; 40mg+5mg+12,5mg 84tk; 40mg+5mg+12,5mg 56tk; 40mg+5mg+12,5mg 300tk; 40mg+5mg+12,5mg 280tk; 40mg+5mg+12,5mg 14tk

Estonie - estonien - Ravimiamet

alembic pharmaceuticals europe limited - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+5mg+25mg 10tk; 40mg+5mg+25mg 280tk; 40mg+5mg+25mg 300tk; 40mg+5mg+25mg 7tk; 40mg+5mg+25mg 84tk; 40mg+5mg+25mg 500tk; 40mg+5mg+25mg 28tk; 40mg+5mg+25mg 90tk; 40mg+5mg+25mg 14tk; 40mg+5mg+25mg 30tk

Estonie - estonien - Ravimiamet

alembic pharmaceuticals europe limited - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+10mg+25mg 10tk; 40mg+10mg+25mg 14tk; 40mg+10mg+25mg 30tk; 40mg+10mg+25mg 56tk; 40mg+10mg+25mg 280tk; 40mg+10mg+25mg 84tk; 40mg+10mg+25mg 28tk; 40mg+10mg+25mg 90tk; 40mg+10mg+25mg 500tk

Estonie - estonien - Ravimiamet

alembic pharmaceuticals europe limited - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+10mg+12,5mg 50tk; 40mg+10mg+12,5mg 98tk; 40mg+10mg+12,5mg 14tk; 40mg+10mg+12,5mg 28tk; 40mg+10mg+12,5mg 7tk; 40mg+10mg+12,5mg 10tk; 40mg+10mg+12,5mg 500tk; 40mg+10mg+12,5mg 90tk; 40mg+10mg+12,5mg 300tk; 40mg+10mg+12,5mg 280tk; 40mg+10mg+12,5mg 56tk; 40mg+10mg+12,5mg 84tk; 40mg+10mg+12,5mg 30tk

Estonie - estonien - Ravimiamet

alembic pharmaceuticals europe limited - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 20mg+5mg+12,5mg 50tk; 20mg+5mg+12,5mg 280tk; 20mg+5mg+12,5mg 14tk; 20mg+5mg+12,5mg 7tk; 20mg+5mg+12,5mg 98tk; 20mg+5mg+12,5mg 56tk; 20mg+5mg+12,5mg 300tk; 20mg+5mg+12,5mg 500tk; 20mg+5mg+12,5mg 28tk; 20mg+5mg+12,5mg 90tk; 20mg+5mg+12,5mg 84tk

Union européenne - estonien - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Union européenne - estonien - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - estonien - EMA (European Medicines Agency)

mylan pharmaceuticals limited - amlodipine besilate, valsartan - hüpertensioon - reniini-angiotensiini süsteemi toimivad ained - essentsiaalse hüpertensiooni ravi. amlodipine/valsartan mylan on näidustatud täiskasvanutel, kelle vererõhk ei ole adekvaatselt kontrollitav kohta amlodipine või valsartan monotherapy.

Union européenne - estonien - EMA (European Medicines Agency)

pfizer europe ma eeig - levetiratsetaam - epilepsia - antiepileptics, - levetiracetam hospira on näidustatud monoteraapiana partsiaalsete krampide puhul koos või ilma sekundaarse generaliseerumisega täiskasvanutel ja noorukitel alates 16 aasta vanusest äsja diagnoositud epilepsia. levetiracetam hospira on näidustatud adjunctive therapyin ravi osaline algusega krambid koos või ilma sekundaarse teha üldistusi täiskasvanud, noorukid ja lapsed alates 4-aastastel epilepsia. ravi myoclonic krampide täiskasvanutele ja noorukitele alates 12 aasta vanusest juveniilse myoclonic epilepsia. ravi esmane üldistatud tonic-clonic krambid täiskasvanutel ja noorukitel alates 12-aastastel idiopaatilise generaliseerunud epilepsia. levetiracetam hospira kontsentraat on alternatiiv patsientidel, kui suukaudne manustamine ei ole ajutiselt võimalik.

Union européenne - estonien - EMA (European Medicines Agency)

pfizer europe ma eeig - krizotiniib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.